Table 2.
Treatment patterns of metformin and concomitant therapies.
| Parameters | Number of patients (N = 5695)* |
|---|---|
| Metformin drug dosage per day, n (%) | |
| Metformin 1500 mg | 1656 (29.1) |
| Metformin 1700 mg | 386 (6.7) |
| Metformin 1850 mg | 136 (2.4) |
| Metformin 2000 mg | 3267 (57.4) |
| Metformin 2250 mg | 90 (1.6) |
| Metformin 2500 mg | 159 (2.8) |
| Metformin: Frequency of dose, n (%) [n = 5574] | |
| OD | 244 (4.4) |
| BD | 5252 (94.2) |
| QID | 78 (1.4) |
| Metformin: Duration of treatment (mo), median (IQR) [n = 5092] | 24.0 (7.0-36.0) |
| Concomitant anti-diabetic medication, n (%) [n = 4667] | |
| Sulfonylureas | 3123 (66.9) |
| DPP4i | 2429 (52.0) |
| SGLT2i | 554 (11.8) |
| AGIs | 350 (7.5) |
| Thiazolidinedione | 327 (7.0) |
| Insulin | 287 (6.1) |
| GLP1 agonist | 25 (0.5) |
| Concomitant non-diabetic medications, n (%) [n = 6022] | |
| Antihypertensives | 2978 (49.5) |
| Statins | 1476 (24.5) |
| Non-steroidal anti-inflammatory | 354 (5.9) |
| Non-statin lipid lowering agents | 56 (0.9) |
| Others | 874 (14.5) |
Abbreviations: AGIs, alpha-glucosidase inhibitors; BD, twice a day; DPP4i, dipeptidyl peptidase-4 inhibitors; FPG, fasting plasma glucose; GLP1, glucagon-like peptide-1; IQR, interquartile range; OD, once a day; PPG, postprandial plasma glucose; QID, quater in die; SGLT2i, sodium-glucose co-transporter-2 inhibitor.
Others, patients who were on concomitant non-diabetic medication including antiallergic, antianxiety, antibiotic, anticonvulsant, antiemetic, antihistamine, antiplatelet, diuretic, hyperthyroidism, hypothyroidism, antiasthmatic, antacid, neuropathic pain, vitamins, and multivitamins.
*
N = 5695, unless otherwise specified.